299. 嚢胞性線維症
[臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
17 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-001440-18-NL
(EUCTR)
30/05/201816/01/2018The influence of cytochrome P450 3A4 inhibitors on serum levels of Ivacaftor in cystic fibrosis patients and healthy subjects.Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in cystic fibrosis patients and healthy controls - IACI cystic fibrosis and healthy subjects;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: Ivacaftor
Trade Name: claritromycin 500mg film coated tablets
Product Name: Claritromycin
Trade Name: Azithromycin 500 mg film-coated tablet
Product Name: azithromycin
Trade Name: Norvir 100 mg film-coated tablets
Product Name: Norvir
university medical center utrechtNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Phase 4Netherlands
2NCT02677701
(ClinicalTrials.gov)
October 21, 201629/1/2016Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)TEACH Trial: Testing the Effect of Adding CHronic Azithromycin to Inhaled Tobramycin. A Randomized, Placebo-controlled, Double-blinded Trial of Azithromycin 500mg Thrice Weekly in Combination With Inhaled TobramycinCystic FibrosisDrug: azithromycin;Drug: placebo (for azithromycin);Drug: inhaled tobramycinSeattle Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI);Cystic Fibrosis Foundation;CF Therapeutics Development Network Coordinating CenterCompleted12 YearsN/AAll119Phase 4United States
3NCT02531984
(ClinicalTrials.gov)
August 201521/8/2015The Efficacy of Azithromycin in Treating Children With Non Cystic Fibrosis BronchiectasisOpen Trial With Randomized Withdrawal of Treatment, to Evaluate the Efficacy of Azithromycin in the Treatment of Children With Non Cystic Fibrosis Bronchiectasis ( AZI-STOP Study )Non Cystic Fibrosis Bronchiectasis in ChildrenDrug: AzithromycinAssistance Publique Hopitaux De MarseilleNULLActive, not recruiting3 Years17 YearsBoth100Phase 3NULL
4NCT02372383
(ClinicalTrials.gov)
October 201420/6/2014Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic FibrosisPharmacokinetic Evaluation of Nontuberculous Mycobacterial Antibiotics in Cystic Fibrosis Versus ControlsCystic FibrosisDrug: Ethambutol;Drug: Rifampin;Drug: Azithromycin;Drug: PancrelipaseUniversity of Colorado, DenverCystic Fibrosis Foundation Therapeutics;Colorado Clinical & Translational Sciences InstituteCompleted16 Years45 YearsBoth32N/AUnited States
5NCT02803944
(ClinicalTrials.gov)
September 201414/6/2016Continuous Azithromycin in Cystic Fibrosis Patients Beyond Two YearsLong Term Effects of Azithromycin in Patients With Cystic Fibrosis Using the National DatabaseCystic FibrosisDrug: AzithromycinHospices Civils de LyonNULLCompleted7 YearsN/ABoth2055N/AFrance
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02054156
(ClinicalTrials.gov)
June 20141/2/2014OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic FibrosisOPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized TrialCystic FibrosisDrug: azithromycin;Drug: placebo;Drug: Tobramycin solution for inhalationBonnie RamseyNational Heart, Lung, and Blood Institute (NHLBI)Completed6 Months18 YearsAll221Phase 3United States
7NCT01270074
(ClinicalTrials.gov)
April 201223/12/2010Prevention of Bronchiectasis in Infants With Cystic FibrosisA Phase 3 Multi-centre Randomised Placebo-controlled Study of Azithromycin in the Primary Prevention of Radiologically-defined Bronchiectasis in Infants With Cystic Fibrosis.Cystic Fibrosis;BronchiectasisDrug: Azithromycin;Drug: Placebo controlThe University of QueenslandTelethon Kids InstituteActive, not recruiting6 Weeks6 MonthsAll132Phase 3Australia;New Zealand
8NCT03045198
(ClinicalTrials.gov)
March 20122/2/2017Effect of Azithromycin on Fatty Acids in CFEffect of Azithromycin on Lipoproteins and Docosahexaenoic Acid in Patients With Cystic FibrosisCystic FibrosisDrug: AzithromycinUniversity Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)University of Bonn;University Hospital, FrankfurtUnknown status10 Years60 YearsAll20Phase 4NULL
9EUCTR2006-003275-12-NO
(EUCTR)
03/06/200927/03/2009Scandinavian Cystic Fibrosis Azithromycin StudySupplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprofloxacin; postponing next isolate of pseudomonas and prevention of chronic infection. A prospective, double-blinded, placebo-controlled scandinavian multi-centre study. A investigator initiated study - Scandinavian Cystic Fibrosis Azithromycin StudyScandinavian Cystic Fibrosis Azithromycin StudySupplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprofloxacin; postponing next isolate of pseudomonas and prevention of chronic infection. A prospective, double-blinded, placebo-controlled scandinavian multi-centre study. A investigator initiated study - Scandinavian Cystic Fibrosis Azithromycin Study Cystic fibrosis with intermittent colonization of the airways with pseudomonas aeruginosa.
MedDRA version: 8.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung
Trade Name: Zitromax
Product Name: Zitromax
Product Code: Zitromax
INN or Proposed INN: AZITHROMYCIN
Trade Name: Zitromax
Product Name: zitromax
Product Code: zitromax
INN or Proposed INN: AZITHROMYCIN
Copenhagen CF-centreNULLNAFemale: yes
Male: yes
250Phase 4Denmark;Norway;Sweden
10NCT00411736
(ClinicalTrials.gov)
May 200814/12/2006Scandinavian Cystic Fibrosis Azithromycin StudySupplementary Oral Azithromycin in Treatment of Intermittent Pseudomonas Aeruginosa Colonization in CF-patients With Inhaled Colistin and Oral Ciprofloxacin; Postponing Next Isolate of Pseudomonas and Prevention of Chronic Infection. A Prospective, Double-blinded, Placebo-controlled Scandinavian Multi-centre Study.Cystic FibrosisDrug: Study medication, azithromycin or placebo;Drug: Azithromycin or placebo tabletsRigshospitalet, DenmarkCystic Fibrosis Foundation TherapeuticsCompleted1 YearN/ABoth45Phase 4Denmark;Norway;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2006-003275-12-DK
(EUCTR)
23/05/200717/04/2007Scandinavian Cystic Fibrosis Azithromycin StudySupplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprofloxacin; postponing next isolate of pseudomonas and prevention of chronic infection. A prospective, double-blinded, placebo-controlled scandinavian multi-centre study. A investigator initiated study - Scandinavian Cystic Fibrosis Azithromycin StudyScandinavian Cystic Fibrosis Azithromycin StudySupplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprofloxacin; postponing next isolate of pseudomonas and prevention of chronic infection. A prospective, double-blinded, placebo-controlled scandinavian multi-centre study. A investigator initiated study - Scandinavian Cystic Fibrosis Azithromycin Study Cystic fibrosis with intermittent colonization of the airways with pseudomonas aeruginosa.
MedDRA version: 8.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis lung
Trade Name: Zitromax
Product Name: zitromax
Product Code: zitromax
INN or Proposed INN: AZITHROMYCIN
Trade Name: Zitromax
Product Name: zitromax
Product Code: zitromax
INN or Proposed INN: AZITHROMYCIN
Copenhagen CF-centreNULLNot RecruitingFemale: yes
Male: yes
250Phase 4Denmark
12NCT00431964
(ClinicalTrials.gov)
February 20072/2/2007Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. AeruginosaMulti-center, Multi-national, Randomized, Placebo-Controlled Trial of Azithromycin in Subjects With Cystic Fibrosis 6-18 Years Old, Culture Negative for Pseudomonas AeruginosaCystic FibrosisDrug: azithromycin 250 mg tablets;Drug: placebo tabletsCF Therapeutics Development Network Coordinating CenterCystic Fibrosis Foundation TherapeuticsCompleted6 Years18 YearsAll263Phase 4United States;Canada
13NCT01463371
(ClinicalTrials.gov)
October 200628/10/2011Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With BronchiectasisEffects of Long-Term Azithromycin Treatment on Airway Oxidative Stress Markers in Patients With Stable Non-Cystic Fibrosis BronchiectasisBronchiectasisDrug: AzithromycinInstituto de Investigacion Sanitaria La FeSociedad Valenciana de NeumologíaCompleted16 Years80 YearsBoth30N/ASpain
14NCT00298922
(ClinicalTrials.gov)
February 20062/3/2006Azithromycin in Patients With CF, Infected With Burkholderia Cepacia ComplexPhase II, Randomized, Double Blind, Placebo-Controlled Trial of Azithromycin in Patients With CF, Chronically Infected With Burkholderia Cepacia ComplexCystic FibrosisDrug: Azithromycin;Drug: PlaceboSt. Michael's Hospital, TorontoCystic Fibrosis Foundation Therapeutics;PfizerActive, not recruiting19 YearsN/ABoth45Phase 2Canada
15NCT00153634
(ClinicalTrials.gov)
March 20048/9/2005Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)Standard vs. Biofilm Susceptibility Testing in CFCystic Fibrosis;Chronic BronchitisDrug: IV amikacin;Drug: PO azithromycin;Drug: IV ceftazidime;Drug: PO ciprofloxacin;Drug: IV meropenem;Drug: IV piperacillin-tazobactam;Drug: IV ticarcillin-clavulanate;Drug: IV tobramycinSeattle Children's HospitalCystic Fibrosis Foundation TherapeuticsCompleted14 YearsN/ABoth75N/AUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16EUCTR2006-003275-12-SE
(EUCTR)
07/07/2009Scandinavian Cystic Fibrosis Azithromycin StudySupplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprofloxacin; postponing next isolate of pseudomonas and prevention of chronic infection. A prospective, double-blinded, placebo-controlled scandinavian multi-centre study. A investigator initiated study - Scandinavian Cystic Fibrosis Azithromycin StudyScandinavian Cystic Fibrosis Azithromycin StudySupplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprofloxacin; postponing next isolate of pseudomonas and prevention of chronic infection. A prospective, double-blinded, placebo-controlled scandinavian multi-centre study. A investigator initiated study - Scandinavian Cystic Fibrosis Azithromycin Study Cystic fibrosis with intermittent colonization of the airways with pseudomonas aeruginosa.
MedDRA version: 14.0;Level: PT;Classification code 10011763;Term: Cystic fibrosis lung;System Organ Class: 10010331 - Congenital, familial and genetic disorders
Trade Name: Azithromycin
Product Name: azithromycin
Product Code: azithromycin
INN or Proposed INN: AZITHROMYCIN
Trade Name: Zitromax
Product Name: zitromax
Product Code: zitromax
INN or Proposed INN: AZITHROMYCIN
Copenhagen CF-centreNULLNAFemale: yes
Male: yes
250Phase 4Denmark;Norway;Sweden
17EUCTR2014-003023-22-FR
(EUCTR)
22/06/2015Open trial with randomized withdrawal of treatment, to evaluate the efficacy of azithromycin in the treatment of bronchiectasis excluding cystic fibrosis in children (AZI-STOP study)Open trial with randomized withdrawal of treatment, to evaluate the efficacy of azithromycin in the treatment of bronchiectasis excluding cystic fibrosis in children (AZI-STOP study) - AZI-STOP study bronchiectasis excluding cystic fibrosis in children;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Trade Name: ZITHOMAX 40 mg/ml ENFANTS
Product Name: zithromax
INN or Proposed INN: AZITHROMYCIN DIHYDRATE
Trade Name: ZITHROMAX 250 mg
Product Name: ZITHROMAX
INN or Proposed INN: AZITHROMYCIN DIHYDRATE
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLENULLNot RecruitingFemale: yes
Male: yes
100Phase 3France